I am asked quite often how I have managed to stick around as an options trader for as long as I have – more than fifteen years and counting. The long answer is that I’ve studied my successes and f...
Add Morgan Stanley to the list of banks who are lashing out against the Fed’s interminable easy monetary policy (as we pointed out last week, the most notable recent entrant was Bank of America ...
Every cycle, a parade of fresh-faced financial analysts salespeople are commissioned to keep the gullible masses buying ‘investment’ products against all odds. Last week, Kate Moore–who began...
Unfortunately, BLK did not meet market expectations and underperformed on Q2 EPS and revenue expectations. Estimize predicted the world’s largest asset manager to post EPS of $5.40 and Wall Street p...
The Chart of the Day is the break-out chart of Orion Engineered Carbons (OEC). I found the carbon black stock by using Barchart to sort today’s All Time High list first by the most frequ...
Immune Pharmaceuticals (Nasdaq: IMNP), a biopharmaceutical company undergoing a restructuring to split its wide-ranging, diversified portfolio into two pure play companies, has garnered much media att...
Note: The charts in this commentary have been updated to include Friday’s Consumer Price Index news release. Back in 2010, the Fed justified its aggressive monetary policy “to promote a...
WOODCLIFF LAKE, N.J., July 17, 2017 (GLOBE NEWSWIRE) — I.D. Systems, Inc. (Nasdaq:IDSY) (“I.D. Systems” or the “Company”) today announced the closing of its previously announced underw...
Photo Credit: Global Panorama Netflix has some interesting stats to pay attention to this quarter. There is a 13% difference in Estimize and Wall Street’s EPS estimates for FQ2’17, $0.18 and $...